ASLAN Pharma Published Positive Phase I Data for It's Bone Loss Drug, ASLAN002

Science Translational Medicine, a peer-reviewed journal, has published new data from a Phase I study of ASLAN002 (BMS777607), ASLAN Pharmaceuticals’ small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON kinase. The data show that inhibition of RON reduces osteoclast bone absorption and indicate that RON signalling in the osteoclast is a new target for treating pathogenic bone loss in the settings of osteoporosis and bone lytic cancers such as breast, lung, prostate, kidney and thyroid. More details.... Share this with colleagues: // //